Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

First Posted Date
2023-03-13
Last Posted Date
2024-06-20
Lead Sponsor
Sichuan University
Target Recruit Count
61
Registration Number
NCT05765825
Locations
🇨🇳

GuiZhou Provincial People's Hospital, Guiyang, China

🇨🇳

Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China

🇨🇳

Chongqing University cancer hospital, Chongqing, Chongqing, China

and more 5 locations

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

First Posted Date
2023-03-13
Last Posted Date
2023-03-13
Lead Sponsor
Zhujiang Hospital
Target Recruit Count
90
Registration Number
NCT05766605
Locations
🇨🇳

Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

First Posted Date
2023-03-03
Last Posted Date
2023-09-21
Lead Sponsor
Mayo Clinic
Target Recruit Count
20
Registration Number
NCT05753306
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

First Posted Date
2023-03-02
Last Posted Date
2023-07-12
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
54
Registration Number
NCT05751187
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, China

Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma

First Posted Date
2023-02-21
Last Posted Date
2024-07-05
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Registration Number
NCT05738161

Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics

First Posted Date
2023-02-16
Last Posted Date
2023-02-16
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
200
Registration Number
NCT05730777
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

First Posted Date
2023-02-13
Last Posted Date
2024-10-16
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
28
Registration Number
NCT05726370
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 3
Recruiting
Conditions
Metastatic Hypopharyngeal Squamous Cell Carcinoma
Metastatic Laryngeal Squamous Cell Carcinoma
Stage IV Laryngeal Cancer AJCC v8
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage IV Hypopharyngeal Carcinoma AJCC v8
Stage IV Lip and Oral Cavity Cancer AJCC v8
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Interventions
Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Fluorouracil
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
First Posted Date
2023-02-10
Last Posted Date
2024-11-28
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
290
Registration Number
NCT05721755
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Carle Physician Group-Effingham, Effingham, Illinois, United States

🇺🇸

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States

and more 48 locations

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

First Posted Date
2023-02-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
377
Registration Number
NCT05722015
Locations
🇭🇺

Törökbálinti Tüdőgyógyintézet ( Site 2105), Törökbálint, Pest, Hungary

🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207), Kaohsiung, Taiwan

🇺🇸

St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023), Phoenix, Arizona, United States

and more 107 locations

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

First Posted Date
2023-02-08
Last Posted Date
2023-02-08
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
368
Registration Number
NCT05715840
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy